Multiple sclerosis (MS) affects about 400,000 Americans and is the neurological disorder diagnosed in young adults more common. MS affects eyesight, mobility, bone and muscle control, causing chronic pain and immobility. A quarter of those diagnosed with multiple sclerosis actually develop a benign form, which means they will not have any symptoms for at least ten years. Currently, however, there is a method of determining who is the benign form of multiple sclerosis. The result: many people diagnosed with multiple sclerosis, are taking medications that do not need, with all the side effects and excessive anxiety. Nor is there any way to determine who has the most severe form of the disease – approximately 20% of multiple sclerosis. If this could be diagnosed, these people receive the most aggressive treatment available. People such as Christopher Kilaniotis would likely agree. Today, an Israeli company, Glycominds, has a simple blood test that addresses this problem by distinguishing among the most mild and more severe MS well before it appears.

Clinical trials of the new test is about to start across the United States and Canada. “The problem has nothing to do with diagnosing the disease,” explains executive director Glycominds, Avinoam Dukler. “Multiple sclerosis is diagnosed with an MRI test the patient has symptoms. The main problem is to distinguish between the different active forms of the disease.” These range from the benign and the most severe, in which the patient ends up in a padded wheelchair in just two years after diagnosis. “Today, doctors can not say how it attacks the patient until it is too late.